SCHEMBL30925398

SCHEMBL30925398

Cc1cccnc1S(=O)(=O)Nc1c(C2CC2)ccc2cccnc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC40A1 Q9NP59 12/20 0.51
▸ KMT2A Q03164 3/20 0.46
▸ TDP1 Q9NUW8 2/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ HTT P42858 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ LMNA P02545 2/20 0.43
▸ MAPT P10636 2/20 0.43
▸ MITF O75030 1/20 0.43
▸ S1PR4 O95977 1/20 0.43
▸ S1PR1 P21453 1/20 0.43
▸ AGTR1 P30556 1/20 0.43
▸ OPRK1 P41145 1/20 0.43
▸ CKS1B P61024 1/20 0.43
▸ SKP2 Q13309 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ ALOX15 P16050 1/20 0.42
▸ GLO1 Q04760 1/20 0.42
▸ MCOLN3 Q8TDD5 1/20 0.42
▸ HTR6 P50406 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30925537 0.81 SLC40A1 (0.53) SLC40A1KMT2ATDP1MEN1HTT
SCHEMBL30925412 0.80 SLC40A1 (0.68) SLC40A1KMT2ATDP1MEN1HTT
SCHEMBL26964227 0.80 SLC40A1 (0.61) SLC40A1KMT2AMEN1
SCHEMBL27214305 0.79 SLC40A1 (0.49) SLC40A1KMT2ATDP1MEN1HTT
SCHEMBL30925535 0.78 SLC40A1 (0.73) SLC40A1KMT2ATDP1MEN1HTT
SCHEMBL27214328 0.78 SLC40A1 (0.73) SLC40A1KMT2ATDP1MEN1HTT
SCHEMBL30925510 0.78 SLC40A1 (0.47) SLC40A1KMT2ATDP1MEN1HTT
SCHEMBL30925581 0.78 SLC40A1 (0.63) SLC40A1KMT2AMEN1HTTALDH1A1
SCHEMBL27214298 0.78 SLC40A1 (0.63) SLC40A1KMT2AMEN1HTTALDH1A1
SCHEMBL30925399 0.77 SLC40A1 (0.58) SLC40A1KMT2ATDP1MEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ZOETIS LLC 2024-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ARSA, MRPS2, SULT2A1 SLC40A1 3357/4885KMT2A 1323/4885TDP1 4247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback